Surgery

The FDA 510(k) clearance K040187 (June 21, 2004; Ricarimpex SAS) specifies two indications: (1) serving as an adjunct to the healing of graft tissue when venous congestion may delay healing, and (2) overcoming venous congestion by creating prolonged localized bleeding. A second supplier — Biopharm (UK) Ltd. — received 510(k) clearance K132958 in 2014. Biopharm's submission identifies its device as Hirudo verbana, whereas K040187 names Hirudo medicinalis; Siddall et al. (2007, Proc R Soc B) showed that commercially marketed leeches sold as H. medicinalis are actually H. verbana. Both clearances fall under the same FDA product code (NRN).

On December 30, 2024, the FDA transferred regulatory responsibility for medicinal leeches from the Center for Devices and Radiological Health (CDRH) to the Center for Biologics Evaluation and Research (CBER). This administrative transfer does not affect clinical use or availability.

The aggregate evidence across three systematic reviews and one narrative review reports salvage rates of about 75-78% for venous-congested tissue transfers (Whitaker 2012: 77.98%; Rajaram 2024: 75%), within a 65-85% range reported by Herlin 2017 (83.7% in its own series). The mechanism combines three concurrent actions: active blood extraction by the leech (5-15 mL per feeding); pharmacologic anticoagulation via hirudin (direct thrombin inhibition), calin/saratin (inhibition of platelet adhesion to collagen / von Willebrand factor), and factor Xa inhibitors; and sustained post-detachment bleeding lasting 4 to 24 hours, providing continued venous decompression after the leech detaches. This combination is not currently replicated by available synthetic devices or pharmaceuticals.

Venous congestion is the most common cause of flap failure. When the venous pedicle is thrombosed or the venous anastomosis is compromised, the flap develops progressive edema, cyanosis, and capillary refill failure. Without intervention, ischemic necrosis follows within hours. Medicinal leech therapy addresses this emergency through three concurrent mechanisms:

Digit replantation, particularly of distal fingertips where veins are too small for microsurgical anastomosis (typically distal to the DIP joint), represents one of the most established applications of medicinal leech therapy. The distal digital venous system is too fine for reliable microvascular repair — arterial inflow can be re-established, but venous outflow cannot. Without venous decompression, the replanted digit develops progressive congestion and necrosis. Medicinal leeches provide an effective bridge to neovascularization (typically 5-7 days).

A critical clinical question: should leeches be applied prophylactically (immediately after replantation, before clinical congestion develops) or reactively (only when congestion signs appear)? Retrospective data from 25 distal digit replantations shows a substantial advantage for the prophylactic approach:

Ear replantation presents a unique microsurgical challenge: the external ear has a limited number of veins, and venous anastomosis is frequently impossible — particularly in crush or avulsion injuries where venous structures are destroyed. For decades, this made total ear replantation technically possible but clinically unreliable. The introduction of medicinal leech therapy addressed this clinical challenge by providing a reliable alternative venous outflow pathway.

A literature review by Concannon and Puckett (1998) found that external venous decompression was needed in 57% of ear replantations and reported a salvage rate of 80% after replantation; a 2026 systematic review of 92 microvascular ear replantations found success in 17 of 25 artery-only cases (68.0%) versus 58 of 64 (90.6%) with venous repair — a notable outcome for a procedure that was previously considered impractical when venous repair was impossible. The key insight: artery-only replantation (arterial inflow without venous outflow) is viable when leeches provide bridge venous decompression until neovascularization establishes new venous channels (typically 5-7 days).

Breast reconstruction using autologous tissue transfer (TRAM and DIEP flaps) carries a significant risk of venous congestion due to the large tissue volume and the technical demands of microsurgical pedicle dissection. Rajaram et al. (2024) systematically reviewed 18 studies (combined n=28) of medicinal leeching in breast surgery and reported a 75% salvage rate with leech therapy. The complication rate was notably high at 81.14%, largely infection and anaemia, with anaemia associated with increased leech burden and likely multifactorial (including intraoperative blood loss or postoperative haematoma).

The disparity between breast flap outcomes and other tissue transfers reflects fundamental biology: larger flaps have more tissue volume requiring decompression, longer treatment courses, greater transfusion requirements, and higher infection risk due to prolonged leech contact. Nguyen et al. (2012) documented that regional and free flaps achieved only 33.3% salvage with leech therapy, compared with no total losses in native skin and local flaps — though this difference likely reflects the severity of the underlying vascular compromise rather than treatment failure.

Head and neck reconstruction after malignant tumor resection frequently requires free tissue transfer to restore function and form. Leech therapy is used in this context to relieve venous congestion in reconstructive flaps of the head and neck, contributing to transplant viability, though controlled outcome data are lacking.

Tissue transfers to burn wound beds face heightened risk of venous congestion due to scarred, fibrotic, and poorly vascularized recipient tissue. The anti-inflammatory properties of leech SGS (bdellins, eglins, complement inhibitors) may provide additional benefit in the chronic inflammatory milieu of burn scars. Although no dedicated clinical study has examined leech therapy specifically for burn reconstruction, the mechanism of action — local venous decompression with anti-inflammatory modulation — applies directly to this context.

Keloids remain a persistent challenge in plastic surgery, with recurrence rates of 45-100% after excision alone and 10-50% even with adjuvant therapy (corticosteroid injection, radiation, pressure therapy, silicone sheeting). Two properties of leech SGS suggest a potential role in keloid management: destabilase-mediated fibrinolytic activity (destabilase is an endo-epsilon-(gamma-Glu)-Lys isopeptidase that cleaves cross-links in stabilized fibrin; an effect on keloid collagen has not been demonstrated) and anti-inflammatory effects (which may modulate the chronic inflammatory state that drives keloid formation through TGF-beta-mediated fibroblast activation).

Improved microcirculation from leech therapy is a plausible mechanism for scar remodeling, and Russian practitioners report using it on post-traumatic and gunshot wound scars. While gunshot scars differ pathophysiologically from keloids, the underlying mechanism — improved microcirculation with consequent tissue remodeling — is analogous. Clinical evidence for keloid-specific application remains preliminary, and controlled studies comparing leech therapy to established keloid treatments are needed.

Thrombophlebitis is one of the longest-documented surgical indications for leech therapy, with reports dating to Ternier (1922). The modern evidence, however, consists of uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists demonstrating a benefit of leech therapy in thrombophlebitis, and reported patient counts, length-of-stay reductions, and comparative outcomes cannot be confirmed against the primary literature.

The biological rationale is multifactorial: local bloodletting reduces venous hypertension in the affected segment; SGS anticoagulants (hirudin, calin, factor Xa inhibitors) prevent thrombus propagation; destabilase provides thrombolytic activity against stabilized fibrin; and anti-inflammatory components mitigate the perivenous inflammation that characterizes thrombophlebitis. The protocol described in the Russian-language literature involves 3-15 leeches per session placed in a staggered pattern on both sides along the course of the thrombosed vein, about 1 cm from it, once or twice a week for 3-8 sessions (uncontrolled reports; Baskova & Isakhanyan 2004).

Chronic venous disease, including chronic venous insufficiency (CVI), is highly prevalent: in the Vein Consult Program, a survey of 91,545 primary-care patients across 20 countries, 83.6% had signs or symptoms of it and 63.9% had visible signs (CEAP C1–C6) (Rabe et al., 2012). The spectrum ranges from cosmetically concerning telangiectases to debilitating venous ulcers. Leech therapy has been used for CVI for centuries, with the modern evidence base consisting primarily of case series.

Bapat et al. (1998) reported healing of all ulcers in 20 patients with complicated varicose veins. Other favorable outcomes in chronic venous ulcers have been described only in uncontrolled Russian-language reports that are not independently verifiable. While these results are encouraging, no randomized controlled trials compare leech therapy to compression therapy, surgical correction, or modern endovenous ablation for CVI.

Post-thrombotic syndrome (PTS) develops in 20-50% of patients after deep vein thrombosis, causing chronic leg pain, swelling, skin changes, and in severe cases, venous ulceration (Kahn et al., 2014, Circulation). Evidence for leech therapy in PTS is limited to uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists. The proposed mechanism includes improved microcirculation in post-phlebitic tissue, anti-inflammatory effects on the chronic inflammatory state of PTS, and destabilase-mediated dissolution of residual thrombus.

Russian traumatology and orthopedics literature anecdotally describes leech therapy for postoperative wound complications following abdominal surgery, chronic post-traumatic soft tissue injuries affecting tendons, ligaments, and fasciae, and post-traumatic stump pain and phantom limb symptoms. However, no controlled trial or specific patient counts and risk-reduction figures could be verified in these contexts.

Developed following the multidrug-resistant case reported in 2020 (Masters et al., J Glob Antimicrob Resist), this single-institution protocol is a published example of proactive leech-batch surveillance:

The implementation of leech therapy in US hospitals has matured from ad hoc bedside application to standardized, protocol-driven care. US-distributed medicinal leeches reach hospital pharmacies through three FDA-cleared 510(k) holders (Ricarimpex SAS, Biopharm UK Ltd., Carolina Biological Supply Co.).

A 2022 cost-effectiveness analysis modeled leech therapy duration thresholds for digit replantation against the widely accepted $100,000/QALY willingness-to-pay benchmark. Current US supplier list prices are about $18-20 per leech (Leeches USA: $20.15 each for 7-99 leeches, $18.15 for 100 or more; Carolina Leeches: $19.95 for 7-50, $18.25 for 51 or more). Leech use per patient varies widely in published series, for example mean 38, 101 and 158 leeches in salvaged, partially salvaged and lost regional and free flaps (Nguyen 2012), which at these prices implies direct biologic costs of roughly $750-$2,900 per patient. Hospitalization costs ranged from $12,622 to $123,563, and the average cost of an additional day of leech therapy was $2,951.

The use of a living organism as a medical device introduces unique patient-interaction considerations. Patient cooperation directly affects treatment success — an anxious, non-cooperative patient makes leech application more difficult and may inadvertently dislodge feeding leeches. Pre-treatment education by nursing staff significantly improves tolerance.

Hirudin, the leech's signature 65-amino-acid thrombin inhibitor, has directly inspired an entire class of FDA-approved anticoagulants. The trajectory from natural product to pharmaceutical agent represents a notable natural-product-to-pharmaceutical translation — culminating in a drug with a Class I ACC/AHA recommendation and peak annual sales of about $636 million (Angiomax, 2014).

The American Society of Hirudotherapy supports the continued development of evidence-based surgical applications of medicinal leech therapy. Priority research areas include: